We use a few cookies

Essential cookies keep the library working. With your permission, we'd also like to use analytics to see what's useful and improve the experience. Read our Privacy Policy or Cookie Policy.

Skip to main content
Home/e-Resources/Medical Sciences/Application of immunohistochemistry in diagnosis and management of malignant mesothelioma
PeriodicalsMedical Sciences

Application of immunohistochemistry in diagnosis and management of malignant mesothelioma

Checking your access to this record.

Abstract & Overview

Abstract: Immunohistochemistry plays an indispensable role in accurate diagnosis of malignant mesothelioma, particularly in morphologically challenging cases and in biopsy and cytology specimens, where tumor architecture is difficult or impossible to evaluate. Application of a targeted panel of mesothelial- and epithelial-specific markers permits correct identification of tumor lineage in the vast majority of cases. An immunopanel including two mesothelial markers (calretinin, CK5/6, WT-1, or D2-40) and two epithelial markers (MOC-31 and claudin-4) offers good sensitivity and specificity, with adjustments as appropriate for the differential diagnosis. Once mesothelial lineage is established, malignancy-specific studies can help verify a diagnosis of malignant mesothelioma. BAP1 loss, CDKN2A homozygous deletion, and MTAP loss are highly specific markers of malignancy in a mesothelial lesion, and they attain acceptable diagnostic sensitivity when applied as a diagnostic panel. Novel markers of malignancy, such as 5-hmC loss and increased EZH2 expression, are promising, but have not yet achieved widespread clinical adoption. Some diagnostic markers also have prognostic significance, and PD-L1 immunohistochemistry may predict tumor response to immunotherapy. Application and interpretation of these immnuomarkers should always be guided by clinical history, radiographic findings, and above all histomorphology.

Cite this record

David B. Chapel, Jefree J. Schulte, Aliya Noor Husain, Thomas N Krausz (2020). Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Translational Lung Cancer Research, 9(S1), S3–S27. https://doi.org/10.21037/tlcr.2019.11.29

Copy in another style

Chapel, D. B., Schulte, J. J., Husain, A. N., & Krausz, T. N. (2020). Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Translational Lung Cancer Research, 9(S1), S3–S27. https://doi.org/10.21037/tlcr.2019.11.29
Author names are used as deposited, so check their order before you submit.

Metadata is harvested from open-access indexes and can be incomplete. Check a citation against the published version before relying on it — see our open access & attribution policy.